- Home
- IMCR
as 11-15-2024 3:36pm EST
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | OXFORDSHIRE |
| Market Cap: | 1.7B | IPO Year: | 2021 |
| Target Price: | $68.73 | AVG Volume (30 days): | 238.6K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.72 - $76.98 | Next Earning Date: | 11-06-2024 |
| Revenue: | $296,312,000 | Revenue Growth: | 25.09% |
| Revenue Growth (this year): | 28.88% | Revenue Growth (next year): | 12.61% |
Latest Immunocore Holdings plc News
IMCR Breaking Stock News: Dive into IMCR Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know
GlobeNewswire
8 days ago
Immunocore to present at upcoming investor conferences
GlobeNewswire
10 days ago
Immunocore reports third quarter financial results and provides a business update
Zacks
11 days ago
Immunocore (IMCR) Upgraded to Buy: Here's Why
MT Newswires
23 days ago
--UBS Initiates Immunocore Holdings With Sell Rating, $24 Price Target
GuruFocus.com
a month ago
Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ...
Insider Monkey
2 months ago
Immunocore Holdings plc (IMCR): Worst 52-Week Low Stock to Buy Now
Insider Monkey
2 months ago
Immunocore Holdings plc (NASDAQ:IMCR) Ranks Low On The List Of Worst Falling Stocks To Buy
Compare IMCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMCR Immunocore Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.